Morgan Stanley
NAVB

Morgan Stanley’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Morgan Stanley’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-4,416
Closed -$396 – 8080
2023
Q3 		$396 Hold
4,416
– – ﹤0.01% 7333
2023
Q2 		$406 Buy
4,416
+4,150
+1,560% +$662 ﹤0.01% 7395
2023
Q1 		$69 Sell
266
-31
-10% -$9 ﹤0.01% 7595
2022
Q4 		$63 Buy
297
+31
+12% +$8 ﹤0.01% 7723
2022
Q3 		$0 Hold
266
– – ﹤0.01% 8220
2022
Q2 		$0 Sell
266
-254
-49% -$216 ﹤0.01% 8332
2022
Q1 		$0 Buy
520
+203
+64% +$186 ﹤0.01% 8406
2021
Q4 		$0 Sell
317
-2,499
-89% -$3.52K ﹤0.01% 8462
2021
Q3 		$5K Sell
2,816
-8,567
-75% -$14.4K ﹤0.01% 7524
2021
Q2 		$21K Sell
11,383
-7,500
-40% -$13.3K ﹤0.01% 7003
2021
Q1 		$38K Buy
18,883
+8,633
+84% +$20.2K ﹤0.01% 6483
2020
Q4 		$22K Buy
10,250
+2,500
+32% +$5.89K ﹤0.01% 6416
2020
Q3 		$21K Hold
7,750
– – ﹤0.01% 6056
2020
Q2 		$31K Hold
7,750
– – ﹤0.01% 5866
2020
Q1 		$6K Sell
7,750
-100
-1% -$110 ﹤0.01% 6178
2019
Q4 		$10K Hold
7,850
– – ﹤0.01% 6271
2019
Q3 		$5K Hold
7,850
– – ﹤0.01% 6384
2019
Q2 		$5K Sell
7,850
-15
-0.2% -$29 ﹤0.01% 6337
2019
Q1 		$22K Buy
7,865
+10
+0.1% +$29 ﹤0.01% 5990
2018
Q4 		$16K Hold
7,855
– – ﹤0.01% 6072
2018
Q3 		$36K Hold
7,855
– – ﹤0.01% 5979
2018
Q2 		$36K Sell
7,855
-488
-6% -$2.55K ﹤0.01% 6001
2018
Q1 		$60K Buy
8,343
+58
+0.7% +$434 ﹤0.01% 5843
2017
Q4 		$59K Sell
8,285
-773
-9% -$6.54K ﹤0.01% 5786
2017
Q3 		$75K Buy
9,058
+226
+3% +$1.92K ﹤0.01% 5658
2017
Q2 		$90K Buy
8,832
+54
+0.6% +$534 ﹤0.01% 5676
2017
Q1 		$102K Buy
8,778
+89
+1% +$1.01K ﹤0.01% 5595
2016
Q4 		$111K Buy
8,689
+284
+3% +$4.5K ﹤0.01% 5540
2016
Q3 		$154K Sell
8,405
-273
-3% -$3.45K ﹤0.01% 5120
2016
Q2 		$92K Sell
8,678
-1,429
-14% -$28.1K ﹤0.01% 5277
2016
Q1 		$191K Sell
10,107
-1,678
-14% -$32.3K ﹤0.01% 5006
2015
Q4 		$314K Buy
11,785
+1,347
+13% +$46.8K ﹤0.01% 4845
2015
Q3 		$476K Buy
10,438
+1,175
+13% +$44.3K ﹤0.01% 4644
2015
Q2 		$298K Sell
9,263
-339
-4% -$9.85K ﹤0.01% 5035
2015
Q1 		$305K Sell
9,602
-2,974
-24% -$101K ﹤0.01% 4964
2014
Q4 		$475K Sell
12,576
-484
-4% -$13.3K ﹤0.01% 4699
2014
Q3 		$345K Buy
13,060
+1,824
+16% +$48.3K ﹤0.01% 4815
2014
Q2 		$333K Buy
11,236
+98
+0.9% +$3.17K ﹤0.01% 4880
2014
Q1 		$412K Buy
11,138
+1,587
+17% +$60.2K ﹤0.01% 4690
2013
Q4 		$396K Sell
9,551
-321
-3% -$12.6K ﹤0.01% 4618
2013
Q3 		$523K Sell
9,872
-1,725
-15% -$101K ﹤0.01% 4298
2013
Q2 		$619K Buy
+11,597
New +$579K ﹤0.01% 4113

Other funds holding NAVB

BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.28B AUM 38.1% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
ASN
Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return

Morgan Stanley's NAVB Position: Q4 2023 in Review

Morgan Stanley sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q4 2023, closing a stake of 4,416 shares — an estimated $396 sold.

Morgan Stanley first reported a position in NAVB in Q2 2013 and held it in 42 quarters. The position peaked at $619K in Q2 2013. 4 funds tracked by Wall St. Rank hold NAVB as of Q4 2023.

  • Morgan Stanley reported no remaining Navidea Biopharmaceuticals Inc. position as of Q4 2023 after selling out during the quarter.
  • Morgan Stanley sold 4,416 Navidea Biopharmaceuticals Inc. shares in Q4 2023, an estimated $396.
  • Morgan Stanley first reported a position in Navidea Biopharmaceuticals Inc. in Q2 2013 and held it in 42 quarters.
  • Morgan Stanley's Navidea Biopharmaceuticals Inc. position peaked at $619K in Q2 2013.
  • 4 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q4 2023.

Based on Morgan Stanley's 13F filing for Q4 2023, filed 13 Feb 2024.